How did the Q2 2025 revenue and earnings per share compare to Wall Street consensus estimates? | DARE (Aug 07, 2025) | Candlesense
DARE

How did the Q2 2025 revenue and earnings per share compare to Wall Street consensus estimates?

Answer

The press release you provided only announces that Daré Bioscience (NASDAQ: DARE) will hold a conference call/webcast on August 14 2025 to discuss its Q2 2025 financial results. It does not include the actual Q2 2025 revenue, earnings per share (EPS), or the Wall Street consensus estimates for those metrics.

Because the specific figures are missing, we cannot determine from this announcement how the company’s Q2 2025 revenue and EPS compare to analysts’ expectations. To answer the question, you would need:

  1. The actual Q2 2025 results (revenue and EPS) that Daré Bioscience disclosed in the call or in a subsequent earnings release.
  2. The Wall Street consensus estimates for Q2 2025 revenue and EPS (typically compiled by data providers such as FactSet, Bloomberg, Thomson Reuters, or S&P Global).

What to do next

  • Listen to the webcast or read the accompanying earnings release (often posted on the company’s investor‑relations website shortly after the call). Those documents will list the reported revenue and EPS.
  • Check analyst consensus data from a financial data platform (e.g., FactSet, Bloomberg, Thomson Reuters, S&P Global). Those platforms publish the average of analysts’ forecasts for each quarter.
  • Compare the two sets of numbers:
    • If actual revenue > consensus revenue, the company beat the estimate.
    • If actual EPS > consensus EPS, the company beat the earnings estimate.
    • Conversely, if the actual figures are lower, the company missed the consensus.

Example of how the comparison is typically presented (hypothetical numbers):

Metric Q2 2025 Actual Wall Street Consensus Variance
Revenue $120 million $115 million +4.3 % (beat)
EPS (diluted) $0.45 $0.42 +7.1 % (beat)

Note: The numbers above are illustrative only and do *not** reflect Daré Bioscience’s actual performance.*

Bottom line

Based solely on the information in the provided news release, we cannot determine how Q2 2025 revenue and EPS compared to Wall Street consensus estimates. You’ll need to obtain the actual earnings figures (from the upcoming call or press release) and the consensus forecasts from a financial data source to make the comparison.

Other Questions About This News

What is the analyst consensus following the release, and how are major institutions altering their positions? How did management’s commentary address competitive threats and market share trends in the women’s‑health biopharma space? Did the earnings call reveal any changes to the shareholder return policy (dividends, share buybacks, or stock‑based compensation)? How did the company’s operating expenses and R&D spend change versus the prior quarter and the same quarter last year? Did the company announce any new product milestones or regulatory updates that could affect future sales? How does the current cash balance and runway compare to the company’s stated runway and financing needs? What guidance is management providing for Q3 and full‑year 2025 revenue, EPS, and cash flow? What is the status of any debt or convertible securities, and are there any upcoming maturities or refinancing plans? What were the key drivers of any revenue growth or decline (e.g., product launches, licensing deals, and geographic performance)? What were the latest updates on the company’s pipeline in women’s health, and how might they affect long‑term valuation? Are there any upcoming catalysts (e.g., IND filings, Phase III trial readouts, or partnership announcements) that could move the stock?